Titre :

Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC

Auteur(s) :

Chauvet, Paul [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Paviglianiti, Annalisa [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Labopin, Myriam [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Labussiere, Hélène [Auteur]
Hospices Civils de Lyon [HCL]
Boissel, Nicolas [Auteur]
Institut de Recherche Saint-Louis - Hématologie Immunologie Oncologie (Département de recherche de l’UFR de médecine ; ex- Institut Universitaire Hématologie-IUH) [IRSL]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Maillard, Natacha [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Ouachee-Chardin, Marie [Auteur]
Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] [IHOPe]
Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Poire, Xavier [Auteur]
Chantepie, Sylvain [Auteur]
CHU Caen
Huynh, Anne [Auteur]
Service Hématologie - IUCT-Oncopole [CHU Toulouse]
Bulabois, Claud E. [Auteur]
Leclerc, Mathieu [Auteur]
Hôpital Henri Mondor
Maury, Sebastien [Auteur]
Hôpital Henri Mondor
Chevallier, Patrice [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Cluzeau, Thomas [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Mear, Jean-Baptiste [Auteur]
Centre Hospitalier Universitaire [Rennes]
Cornillon, Jerôme [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Bilger, Karin [Auteur]
Institut de Cancérologie de Strasbourg Europe [ICANS]
Simand, Célestine [Auteur]
Institut de Cancérologie de Strasbourg Europe [ICANS]
Beguin, Yves [Auteur]
Centre Hospitalier Universitaire de Liège [CHU-Liège]
Rubio, Marie-Thérèse [Auteur]
Ingénierie Moléculaire et Physiopathologie Articulaire [IMoPA]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Brissot, Eolia [Auteur]
Centre de Recherche Saint-Antoine [CRSA]

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant.

Numéro :

58

Pagination :

72–79

Date de publication :

2022-11-19

ISSN :

0268-3369

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of this study is to compare the efficacy and safety ...
Lire la suite >Relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (allo-HCT) still represents a major concern with poor outcomes. The aim of this study is to compare the efficacy and safety of blinatumomab and donor lymphocyte infusion (DLI) versus blinatumomab alone in this setting. This is a multicenter retrospective study from centers of SFGM-TC. All transplanted patients who received blinatumomab salvage therapy were included. Patients who received DLI from 1 month before to 100 days after the starting of blinatumomab were included in the blina-DLI group. Seventy-two patients were included. Medium follow-up was 38 months. Fifty received blinatumomab alone and 22 the association blinatumomab-DLI. Two-year overall survival (OS) was 31% in the blinatumomab group and 43% in the blinatumomab-DLI group (p = 0.31). Studying DLI as a time dependent variable, PFS did not significantly differ between the 2 groups (HR:0.7, 95% CI: 0.4–1.5). In multivariate analysis, DLI was not a prognostic factor for OS, progression-free survival and progression/relapse incidence. Adverse events and graft-versus-disease rates were comparable in the 2 groups. In conclusion, adding DLI between 1 month before and 100 days after start of blinatumomab is safe and does not seem to improve outcomes in B-ALL patients who relapsed after allo-HCT.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T00:17:37Z
2024-03-19T09:34:09Z